The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era
- PMID: 23921881
- DOI: 10.1093/cid/cit423
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era
Abstract
Background: Few studies consider the incidence of individual AIDS-defining illnesses (ADIs) at higher CD4 counts, relevant on a population level for monitoring and resource allocation.
Methods: Individuals from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) aged ≥14 years with ≥1 CD4 count of ≥200 µL between 1998 and 2010 were included. Incidence rates (per 1000 person-years of follow-up [PYFU]) were calculated for each ADI within different CD4 strata; Poisson regression, using generalized estimating equations and robust standard errors, was used to model rates of ADIs with current CD4 ≥500/µL.
Results: A total of 12 135 ADIs occurred at a CD4 count of ≥200 cells/µL among 207 539 persons with 1 154 803 PYFU. Incidence rates declined from 20.5 per 1000 PYFU (95% confidence interval [CI], 20.0-21.1 per 1000 PYFU) with current CD4 200-349 cells/µL to 4.1 per 1000 PYFU (95% CI, 3.6-4.6 per 1000 PYFU) with current CD4 ≥ 1000 cells/µL. Persons with a current CD4 of 500-749 cells/µL had a significantly higher rate of ADIs (adjusted incidence rate ratio [aIRR], 1.20; 95% CI, 1.10-1.32), whereas those with a current CD4 of ≥1000 cells/µL had a similar rate (aIRR, 0.92; 95% CI, .79-1.07), compared to a current CD4 of 750-999 cells/µL. Results were consistent in persons with high or low viral load. Findings were stronger for malignant ADIs (aIRR, 1.52; 95% CI, 1.25-1.86) than for nonmalignant ADIs (aIRR, 1.12; 95% CI, 1.01-1.25), comparing persons with a current CD4 of 500-749 cells/µL to 750-999 cells/µL.
Discussion: The incidence of ADIs was higher in individuals with a current CD4 count of 500-749 cells/µL compared to those with a CD4 count of 750-999 cells/µL, but did not decrease further at higher CD4 counts. Results were similar in patients virologically suppressed on combination antiretroviral therapy, suggesting that immune reconstitution is not complete until the CD4 increases to >750 cells/µL.
Keywords: AIDS defining illnesses; CD4; cART; immune reconstitution; virologic suppression.
Comment in
-
Editorial commentary: Under the spell of the red queen.Clin Infect Dis. 2013 Oct;57(7):1048-50. doi: 10.1093/cid/cit425. Epub 2013 Aug 6. Clin Infect Dis. 2013. PMID: 23921883 No abstract available.
Similar articles
-
Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?Clin Infect Dis. 2010 Sep 1;51(5):611-9. doi: 10.1086/655761. Clin Infect Dis. 2010. PMID: 20645862
-
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE.PLoS Med. 2012;9(3):e1001194. doi: 10.1371/journal.pmed.1001194. Epub 2012 Mar 20. PLoS Med. 2012. PMID: 22448150 Free PMC article.
-
AIDS across Europe, 1994-98: the EuroSIDA study.Lancet. 2000 Jul 22;356(9226):291-6. doi: 10.1016/s0140-6736(00)02504-6. Lancet. 2000. PMID: 11071184
-
Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.Lancet. 2009 Apr 18;373(9672):1352-63. doi: 10.1016/S0140-6736(09)60612-7. Epub 2009 Apr 8. Lancet. 2009. PMID: 19361855 Free PMC article. Review.
-
Discontinuation of Pneumocystis jirovecii pneumonia prophylaxis with CD4 count <200 cells/µL and virologic suppression: a systematic review.PLoS One. 2011;6(12):e28570. doi: 10.1371/journal.pone.0028570. Epub 2011 Dec 16. PLoS One. 2011. PMID: 22194853 Free PMC article. Review.
Cited by
-
Progress in Early Detection of HIV in Tajikistan.Viruses. 2024 Jun 23;16(7):1010. doi: 10.3390/v16071010. Viruses. 2024. PMID: 39066173 Free PMC article.
-
Characteristics and Treatment Response of Patients with HIV Associated Kaposi's Sarcoma in Central Kenya.HIV AIDS (Auckl). 2022 Apr 25;14:207-215. doi: 10.2147/HIV.S359278. eCollection 2022. HIV AIDS (Auckl). 2022. PMID: 38808105 Free PMC article.
-
Factors associated with late initiation of antiretroviral therapy in Iran's HIV/AIDS surveillance data.Sci Rep. 2024 Jan 2;14(1):199. doi: 10.1038/s41598-023-50713-0. Sci Rep. 2024. PMID: 38167855 Free PMC article.
-
A History and Atlas of the Human CD4+ T Helper Cell.Biomedicines. 2023 Sep 23;11(10):2608. doi: 10.3390/biomedicines11102608. Biomedicines. 2023. PMID: 37892982 Free PMC article. Review.
-
Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/μL on ART.PLoS One. 2023 Mar 30;18(3):e0283648. doi: 10.1371/journal.pone.0283648. eCollection 2023. PLoS One. 2023. PMID: 36996018 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials

